

#### B7-H3/CD276

Catalog # PVGS1761

### **Specification**

### **B7-H3/CD276 - Product Information**

Primary Accession **Species** Human

**O5ZPR3-2** 

**Sequence** 

Leu29-Pro245

**Purity** 

> 95% as determined by Bis-Tris PAGE<br/>> > 95% as determined by HPLC

**Endotoxin Level** 

Less than 1EU per µg by the LAL method.

**Biological Activity** 

Immobilized B7-H3/CD276 hFc Chimera, Human (Cat.No.: Z03881) at 2  $\mu$ g/ml (100  $\mu$ l/Well) on the plate can bind Biotinylated Anti-B7-H3 Antibody, hFc Tag.

**Expression System** 

**HEK293** 

**Theoretical Molecular Weight** 

50.1 kDa

Formulation Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4.

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>0 more than 100  $\mu$ g/ml.

Storage & Stability


Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## **B7-H3/CD276 - Additional Information**

# **Target Background**

B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig-B7-H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.

#### **B7-H3/CD276 - Protein Information**





B7-H3/CD276 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

**B7-H3/CD276 - Images**